Tvardi Therapeutics, Inc.
TVRDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of. Valued at $12.5M, TVRD is a micro-cap name in its sector. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Market Cap
$12.5M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-0.43
EPS (TTM)
$-2.84
EPS (Fwd)
$-2.18
ROE
-126.2%
ROA
-55.5%
Cash
$15.8M
Total Debt
$145,000
Free CF
-$16.3M
52W Change
-81.1%
Annual Financials
Cash vs Debt
Where TVRD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TVRD finished 61.81% below its 150-day moving average ($2.54) and 66.67% below its 200-day moving average ($2.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TVRD overbought or oversold?
At the October 20, 2026 close, TVRD's RSI(14) was 21.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $15.8M in cash and $145K in debt, TVRD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$16.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -126.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TVRD.